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ABSTRACT
We describe a patient affected by multiple endocrine neoplasia type
2A (MEN 2A) bearing a heterozygous germline mutation (Cys634Arg)
in exon 11 and an additional somatic mutation of the RET protoon-
cogene. A large intragenic deletion, spanning exon 4 to exon 16,
affected the normal allele and was detected by quantitative PCR,
Southern blot analysis, and screening of several polymorphic mark-
ers. This deletion causes RET loss of heterozygosity exclusively in the
metastasis, thus suggesting a role for this second mutational event in
tumor progression. No additional mutations were found in the other
exons analyzed. We provide the first evidence that RET, a dominant
oncogene, is affected by a germline mutation and by an additional
somatic deletion of the wild-type allele. This unusual genetic profile
may be related to the clinical course and very poor outcome. (J Clin
Endocrinol Metab 86: 239–244, 2001)
MEDULLARY THYROID carcinoma originates from theC cells of the thyroid gland and presents in a spo-
radic form [medullary thyroid carcinoma (MTC)] or as part
of the inherited cancer syndromes, such as multiple endo-
crine neoplasia type 2A (MEN 2A). This syndrome, trans-
mitted in an autosomic dominant fashion, is characterized by
MTC, pheochromocytoma, and hyperplasia of the parathy-
roid glands (1).
The gene responsible for these tumors is the RET protoon-
cogene (2–6), coding for a membrane tyrosine kinase recep-
tor expressed in neural crest-derived cells (7–9). Ninety-five
percent of MEN 2A cases bear point mutations of the RET
gene (10) mainly in exons 10 and 11 (2, 3, 5, 6). Thirty to 50%
of sporadic MTCs cases bear a RET mutation in exon 16
(4, 11–15); less frequent are mutations in other exons (11, 12,
15, 16).
Duplication or deletion of segments of various lengths of
the RET gene take place only occasionally; 9- or 12 bp du-
plications in exon 11 have been reported in a few MEN 2A
cases (17, 18). A 27-bp deletion in exon 10 (19) and a deletion-
insertion in exon 11 have been reported in sporadic MTCs
(20).
In other hereditary tumors, a germline mutation in a pre-
disposing gene is usually followed by functional loss of the
homologous allele in the tumor tissue (21). In these cases the
affected gene acts as a tumor suppressor, and the disease is
established only when both copies of the gene are altered
(22). In MEN 2 tumor DNA, no gross abnormalities are found
at the RET locus, nor are other markers in proximity of the
gene affected. In a percentage of MEN 2-related tumors, loss
of heterozygosity (LOH) on chromosomes 1, 3, 11, 17, and 22
has been described and related to loss of function of putative
suppressor genes (23–29). However, the role of these LOH in
the tumor progression process is not known yet.
Here we report a MEN 2A case affected by a typical het-
erozygous germline mutation (Cys634Arg) in exon 11 and by
an additional somatic deletion of the wild-type allele. The
deletion spans exon 4 to exon 16, does not include extragenic
sequences, and is not associated with base pair changes in
any other mutation-bearing RET exons. This is the first report
of a MEN 2A case with loss of heterozygosity of the RET
gene. This genetic profile may be related to the early onset,
the clinical course with local and distant metastases, and the
very poor outcome.
Materials and Methods
DNA analysis
DNA was extracted from the primary tumor, a metastatic node, and
peripheral blood lymphocytes and used as a template for PCR reactions
performed as previously described (30). RET exons 10, 11, 13, 14, 15, and
16 were amplified using as primers the oligonucleotides reported pre-
viously (4, 5, 31–34). The purified PCR products were sequenced on both
strands with the Sanger method, using the Sequenase PCR product
sequencing kit (U.S. Biochemical Corp., Cleveland, OH) and the primers
used for the amplification. Sequence reactions were then run on 6%
denaturing polyacrylamide gels and autoradiographed overnight. In
some cases, 100–200 ng of the PCR products of exons 2, 11, 13, 14, and
16 amplicons were digested with 2–5 U EagI, BanI and HhaI, AluI, NlaIII,
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or FokI restriction enzymes, respectively (31, 32, 35, 36). Samples were
then run on 2% or 3% agarose gels, and DNA bands were visualized after
ethidium bromide staining. The D10S94 locus was amplified using the
primers described previously (37), and 100–200 ng of the purified PCR
product were digested with 2–5 U PvuII restriction enzyme. Genomic
DNA was also analyzed by Southern blot.
Quantitative PCR procedure
The quantitative PCR analysis was performed as previously de-
scribed (38). The duplex PCR reaction for all RET exons was performed
by amplifying as internal control exon 10 of the piruvate kinase (PK)
gene (39). The primers used for the PK gene were: 10F, 59-CTCGT-
TCACCACTTTCTTGC-39; and 10R, 59-GGGAAGCTGGGTTGGGGGC-
39, both of which were derived from the intronic sequence. The primers
used to amplify the RET exons 10, 11, 13, 14, 15, and 16 were reported
previously (4, 5, 31–34); the others were designed according to the gene
sequence (1). The duplex PCR reactions were performed in a 50-mL final
volume, containing 100–200 ng genomic DNA, 50 mmol/L KCl, 10
mmol/L Tris-HCl (pH 8.3), 1.5 mmol/L MgCl2, 5 mmol/L NH4Cl, 200
mmol/L of each deoxy-NTP, 30 pmol of each primer, 4 mCi (3000 Ci mm)
of 32P-labeled deoxy-CTP, and 2.5 U Taq polymerase (AmpliTaq, Perkin-
Elmer Corp., Norwalk, CT). The PCR cycles were as follows: denatur-
ation step for 7 min at 94 C; 22 cycles of denaturation, annealing, and
extension performed at 94 C for 1 min, 52 C for 2 min, and 72 C for 5
min; and a final elongation step at 72 C for 7 min. The samples were
stored at 4 C until required. Four microliters of each PCR product were
pipetted from each tube and mixed with 1 mL loading dye. The samples
were electrophoresed on a 5% polyacrylamide gel (39:1 acrylamide/
bisacrylamide ratio) in 1 3 Tris Borate EDTA buffer for 1 h at 1800 V.
The gel was dried and exposed on the GS-250 Molecular Imager (Bio-Rad
Laboratories, Inc., Hercules, CA) for about 15–18 h.
Results
Case report
In 1986, a 18-yr-old woman was referred for evaluation to
the Niguarda Hospital and underwent fine needle aspiration
biopsy of a lateral cervical lymph node that had rapidly
enlarged. Histological examination revealed MTC, as con-
firmed by elevated serum calcitonin (314 mg/ml) and carci-
noembryonic antigen (44.5 ng/mL) levels. Total thyroidec-
tomy with central compartment resection was immediately
performed. The thyroid was bilaterally affected by the tumor
that had invaded the neighboring vessels. Local nodes were
metastasized. No clinical signs or symptoms of a pheochro-
mocytoma were present. After treatment and a period of
well-being, the patient complained of general discomfort due
in part to enlargement of the cervical nodes that compressed
the adjacent veins. They were removed, but later the patient
was again hospitalized for respiratory problems due to sev-
eral metastatic infiltrates in both lungs, as revealed by com-
puted tomography. The patient’s general condition progres-
sively worsened, and in February 1995 she died at the age of
27 yr. Her family history was negative for relevant thyroid
pathology.
Identification of RET proto-oncogene mutations
DNA from peripheral blood lymphocytes, primary (1986
surgery) and metastatic (1991 surgery) tumors were ana-
lyzed for RET protooncogene mutations. Exon 11 from pe-
ripheral blood DNA was PCR amplified and sequenced. A
heterozygous TGC to CGC mutation was detected at codon
634 causing a Cys to Arg substitution (Fig. 1, A and B, patient
blood). The heterozygous mutation of germline DNA was
also found in the DNA from the primary tumor (data not
shown). In contrast, DNA from the metastatic node revealed
only the sequence corresponding to the mutated allele (Fig.
1, A and B, patient metastatic tumor). The specific mutation
FIG. 1. Detection of the Cys634Arg mu-
tation in RET protooncogene. RET exon
11 was amplified from constitutive and
metastatic DNA, and the bands were
sequenced on both strands. In A and B,
the products of the direct sequencing of
the coding and noncoding strand, re-
spectively, are shown. The mutated
codon and the corresponding amino acid
change are boxed on the left. The se-
quencing from a normal individual is
also reported as a control.
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was confirmed by HhaI restriction enzyme digestion (data
not shown). A new site for this enzyme is, in fact, generated
by the Cys634Arg mutation (36).
Quantitative PCR analysis identifies RET LOH
We performed phosphorimager-based quantitative PCR
analysis to establish whether the genomic profile detected in
the metastatic DNA was due to RET LOH (38). This assay
entails the quantitative analysis of two 32P-labeled PCR prod-
ucts, a possibly deleted exon vs. a nondeleted exon. Each RET
exon from germline, primary tumor, and metastatic DNA
was coamplified with exon 10 of the PK gene (39) as an
internal control. This gene was chosen because it maps on the
long arm of chromosome 1, and it should not be involved in
any mutation affecting the RET gene located in the centro-
meric region of chromosome 10 (1). Each experiment was
carried out on DNA from the patient and from a normal
individual. The radioactive amplified products were quan-
tified by phosphorimager scanning, and the ratio of the in-
tensity of the RET exon vs. the internal control was referred
to as R. The ratio of the R value of the patient vs. that of a
normal individual was the diagnostic index (DI). If the DI
ranges between 0.8–1, the tested exon is present in two cop-
ies; if the DI ranges between 0.4–0.6, the exon is present in
a single copy. All RET exons amplified from germline and
primary tumor DNA gave a DI between 0.8–1, clearly indi-
cating that they were present in two copies, as in normal
DNA. In contrast, the DI for exons 4–16 amplified from the
metastatic DNA ranged between 0.4–0.6, indicating that
they were in a single copy. RET exons 1–3 and 17–21 had
normal values, indicating that they were preserved on both
alleles. Figure 2 illustrates the results obtained with some
representative exons, i.e. 3, 11, 16, and 17. The histogram
shows the DI obtained with normal DNA and with consti-
tutive, primary, and metastatic tumor DNA from the
proband.
Analysis of polymorphic sites at the RET locus
confirms LOH
To further confirm the results of the quantitative PCR, two
RET intragenic heterozygous polymorphisms were ana-
lyzed. One maps at the Ala45 codon in exon 2, and the second
maps at the Gly691 codon in exon 11 (35). The former poly-
morphism eliminates the restriction site for the enzyme EagI,
the latter eliminates that for BanI. Patient DNA from periph-
eral blood and metastatic tumor were heterozygous for exon
2 polymorphism (Fig. 3A). Exon 2 PCR-amplified products
digested with EagI produced, in both cases, a band of 265 bp,
corresponding to the undigested allele and two bands of 203
and 62 bp derived from the digested allele. In contrast, a
different profile was detected on DNA from peripheral blood
and metastatic tissue analyzed for the polymorphism at exon
11 (Fig. 3B). BanI digestion of the exon 11 PCR product from
peripheral blood yielded a band of 338 bp, corresponding to
the undigested allele and two bands of 269 and 69 bp gen-
erated from the digested allele. In metastatic tumor DNA, the
BanI digestion profile gave only a single high molecular
weight band, corresponding to the undigested allele, indi-
cating that the polymorphism was not retained. In both di-
gestions, DNA from a normal individual showing the same
polymorphism in heterozygosity was used as a positive
control.
A heterozygous polymorphism at the D10S94 locus, lo-
cated at the 39-region of the RET gene (37), was also analyzed
and shown to be retained in metastatic tumor DNA, indi-
cating that deletion of the wild-type RET allele of the met-
astatic node does not involve extragenic sequences (data not
shown).
Southern blot analysis confirms RET LOH
The proband’s genomic DNA from peripheral blood and
metastatic tumor tissue was analyzed by Southern blot. Fig-
ure 3C shows the results of EcoRI and EcoRI/SalI digestions
of patient’s DNAs hybridized with the XhoI/BglII RET com-
plementary DNA (cDNA) fragment, spanning from exon 14
FIG. 2. Quantitative PCR analysis.
The DI reported in the histogram was
calculated on the germline, primary,
and metastatic tumor DNA from the
proband. The DNA from a normal indi-
vidual was used as a control. The DI was
calculated on each RET exon and on
exon 10 of the PK gene (39), which was
coamplified as internal control, as de-
scribed in Materials and Methods. A DI
between 0.8–1 indicates that the tested
exon is present in two copies; if it is
between 0.4–0.6, the exon is present in
a single copy. The results refer to four
representative RET exons (no. 3, 11, 16,
and 17) and to one of three independent
experiments.
RET LOSS OF HETEROZYGOSITY IN MEN 2A 241
to the 39-end of the cDNA (1). Figure 3D shows the results
of the hybridization with the full-length RET cDNA of the
same DNA sample digested with EcoRI (1). The pattern ob-
served corresponds to that expected, except for a 2.8-kb band
present in the germline DNA and absent in the metastatic
tumor DNA. The 2.8-kb band was also observed on the DNA
from two independent normal subjects digested with the
same enzymes. The disappearance of this band in the tumor
DNA could be due to a polymorphic EcoRI site present in the
wild-type allele, downstream from exon 14. This confirms
the RET LOH, because the site is no longer retained in the
metastatic DNA as a consequence of the interstitial deletion
on the wild-type allele. However, from the data obtained, we
cannot establish the type of rearrangement that occurred, i.e.
translocation of part of the gene to another chromosome or
rejoining of the two portions of the gene.
Discussion
Heterozygous point mutations of the RET protooncogene
are responsible for type 2 MENs and some sporadic MTCs.
In this respect, RET functions as a dominant oncogene after
activation by these specific mutations. The pathogenetic
mechanisms underlying these tumors have been clarified. In
the case of MEN 2A, the mutations lead to constitutive ac-
tivation of the RET receptor through a ligand-independent
dimerization mechanism. Constitutive phosphorylation and
altered substrate specificity are invoked in most sporadic
MTCs (40).
The RET mutations underlying all inherited tumor syn-
dromes cause thyroid C cell hyperplasia, which does not
fully explain either tumor progression or the phenotypic
variations observed not only among families with the same
mutations, but also among individuals in the same family
bearing the same mutation (41). Accumulation of genetic
alterations, functional loss of tumor suppressor genes, and
activation of other oncogenes could contribute to tumor de-
velopment. In fact, LOH on chromosomes 1, 3, 11, 17, and 22
has been reported in MEN 2 cases (23–29).
Despite the consolidated idea that RET acts as a dominant
oncogene due to single mutations, other alterations of this
gene have recently been reported in MTC. Simultaneous
germline mutations at exon 10 or 11 and somatic mutations
at codon 918 in exon 16 have been described (34, 42). Miyau-
chi et al. (43) also found a germline mutation at codon 768 in
exon 13 and a concomitant somatic mutation at codon 919 in
exon 16 in a familial MTC. These reports, however, did not
show on which allele the additional somatic mutations oc-
curred. More interestingly, Uchino et al. (44) reported two
sporadic MTCs with point mutations at codons 918 and 919
of exon 16 and at codon 778 of exon 13, respectively. In both
cases, the wild-type allele was absent.
The case analyzed here bears a typical RET MEN/2A
germline mutation in exon 11 (Cys634Arg) and loss of the
wild-type allele in the tumor. In particular, LOH was de-
tected only in the metastasis and not in the primary tumor,
suggesting that this second mutational event had occurred
somatically and that it probably could have played a role in
tumor progression. Our hypothesis is that this LOH may be
related to the clinical course observed. No additional muta-
FIG. 3. Analysis of polymorphic sites at the RET gene and Southern
blot. Two polymorphisms were analyzed on the germline and meta-
static DNA of the proband and on the DNA from a normal individual
bearing the same heterozygous polymorphisms as a control (35). A,
The polymorphism at the Ala45 codon in RET exon 2. B, The poly-
morphism at the Gly691 codon in exon 11. Uncut, The PCR product
before digestions in both cases. The migration of a molecular size
marker (Promega Corp. PCR marker G3161) is also indicated. C,
Fifteen micrograms of the proband’s genomic DNA extracted from
peripheral blood and metastatic tumor were digested with EcoRI and
SalI and hybridized with a BglII/XhoI fragment derived from the
39-portion of RET cDNA as a probe. D, Fifteen micrograms of the same
DNA samples were digested with EcoRI and hybridized with the
full-length EcoRI RET cDNA as a probe. The migration of a size
marker (l HindIII) is reported on the right. An arrow on the left
indicates the 2.8-kb band absent in the metastatic tumor DNA.
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tions were found in other RET exons analyzed (data not
shown). This represents the first report of a MEN 2A case
characterized by a germline mutation and a somatic loss of
the wild-type allele.
The alteration found was a large intragenic deletion of
about 20 kb encompassing exons 4–16 of the RET locus.
These results ruled out a gene conversion event that should
transform the wild-type to the mutated allele. In fact, gene
conversion usually involves larger chromosomal regions and
is detected for genes present in clusters and among nonallelic
copies (45). This was not the case, as the deletion did not
extend to extragenic sequences at the 39-end of the RET gene
and was present only in the metastatic DNA. In addition, the
loss of genetic material at the RET locus was a random event
and was not due to patient’s genome instability. LOH at other
loci distributed either on chromosome 10 or on other chro-
mosomes was tested, but no instability was detected (data
not shown).
We analyzed the rearrangement that occurred at the wild-
type locus by quantitative PCR, Southern blot, and RFLPs of
chromosome 10. Furthermore, the expression study of the
metastatic tissue ruled out that the rearranged wild-type
allele was still transcribed, indicating that the deletion had
irreversibly compromised its architecture and function. In
fact, in addition to the transcripts derived from the mutated
allele, no bands corresponding to shorter or longer wild-type
RET messenger ribonucleic acid, derived from the rear-
ranged copy, were detected by Northern blot or ribonuclease
protection (data not shown).
LOH of tumor suppressor genes has been described in
inherited cancers, classically represented by retinoblastoma.
The genes responsible are inactivated by a germline mutation
in one allele and by somatic loss of the second allele. The
tumorigenic phenotype is manifested only when both copies
are altered, according to Knudson’s two-hit model (22). The
case we report is unusual and novel, because two mutations
were detected in a dominant oncogene. This event does not
appear to be redundant. We hypothesize that the somatic
LOH could add to the effects of the germline mutation,
resulting in an aggressive phenotype, and could represent
the second or one of the subsequent steps in tumor progres-
sion. It was, in fact, found only in two distinct consecutive
metastases at different locations.
We propose a model in which the wild-type RET form
influences the activity of mutated RET species, functioning
as a mitigating factor in the transformation process. In clas-
sical heterozygous MEN 2A, the mutant RET may form either
homodimers, whose activation is ligand independent or het-
erodimeric complexes with wild-type RET, whose activation
may still be ligand dependent. In contrast, in our case the
absence of the wild-type species could allow the mutant RET
to form only constitutively activated homodimers, thus en-
hancing the transduction of mitogenic signals. In fact, wild-
type RET can form complexes with mutant RET, influencing
the amount of active heterodimers exposed on the cell sur-
face (46). This mechanism could explain the rapid tumor
growth, its wide dissemination, the distant and very invasive
metastases, and the poor outcome of the disease. Experi-
ments to test this hypothesis in vitro are underway. More-
over, a larger series of patients needs to be analyzed to make
a correlation between severe symptomatic MTC and the
pathogenetic mechanism we propose.
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